On September 17, 2024 ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, reported that it will participate at the Cell & Gene Therapy International 2024 meeting, to be held September 23-26, 2024 in Boston, MA (Press release, ImmPACT-Bio, SEP 17, 2024, View Source;gene-therapy-international-2024-302248187.html [SID1234646713]). Sylvain Roy, ImmPACT Bio’s chief technology officer, will provide a presentation about cell therapy manufacturing entitled, "Transitioning from Manual to Automated Processing in Autologous CAR T Manufacturing: A Case Study," on Wednesday, September 25, 2024 at 12:00 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"While the efficacy and durability of autologous CAR T therapies remain unparalleled, a key challenge for scalability and continued adoption is the complexity and cost of manufacturing," said Mr. Roy. "At this meeting, ImmPACT Bio will present a case study of transition from an established GMP manual process to an automated, closed-processing manufacturing platform, and address key aspects on the optimization of CAR T-cell therapy manufacturing."